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E-mail: sterghios.moschos@northumbria.ac.ukLow allelic and clonal variability among endogenous RNAi
targets has focused mismatch tolerance studies to RNAi-active
guide strands. However, the inherent genomic instability of
RNA viruses such as hepatitis C virus (HCV) gives rise to
quasi-species mutants within discrete clones: this facilitates
mismatch tolerance studies from a target perspective. We
recently quantiﬁed the slicing imprecision of Argonaute 2 us-
ing small interfering RNA (siRNA) analogs of the DNA-
directed RNAi drug TT-034 and next-generation sequencing
of 50 RNA ligase-mediated rapid ampliﬁcation of cDNA ends
(RACE-SEQ). Here, we present an open-source, customizable,
and computationally light RACE-SEQ bioinformatic pipeline,
describing adaptations that semiquantitatively report the
impact of RNAi hybridization site mismatches from the target
perspective. The analysis shows that Argonaute 2 has a substi-
tution-speciﬁc, 3- to 5-log activity window between fully
complementary targets and targets with mismatches across
positions 10–11. It further focuses the endonucleotic Slicer
imprecision around positions 13–17, demonstrating its depen-
dence on guide strand central region complementarity, and
potentiation by even a single mismatch. We further propose
pharmacogenomics value in testing endogenous targets using
recombinant replicon systems and RACE-SEQ to report the
pharmacodynamics of sequence-speciﬁc oligonucleotide thera-
peutics against all possible polymorphisms in a population, in a
minimally biased, patient-free manner.
INTRODUCTION
RNAi is the biological process by which endogenous or exogenous
RNA molecules drive sequence-speciﬁc changes in gene expression
through RNA-induced silencing complexes. Study of the intrinsic
pathways and co-factors involved in RNAi has shed light on some
of the mechanics of gene expression regulation, spurring signiﬁcant
progress in the development of associated technologies.1 Thus, since
its unexpected discovery,2 RNAi has matured into numerous applica-
tions in plants and is now poised to achieve regulatory approval for
clinical use. Key to clinical success, however, has proven to be the pro-
vision of sustained and pharmacologically rational evidence of an on-
target mechanism of action across the drug development pipeline.322 Molecular Therapy: Nucleic Acids Vol. 9 December 2017 ª 2017 Th
This is an open access article under the CC BY license (http://creativAt the core of RNAi, the RNA-induced silencing complex (RISC) in-
volves an Argonaute protein loaded with a single, 21-nt-long RNA
strand, commonly referred to as the active or guide strand.4,5 The
best-understood mechanism that RISC uses to recognize RNA targets
appears to be the so-called guide strand “seed” sequence between
bases 2–8 from the 50 end of the guide strand,6 short enough to impli-
cate potentially thousands of transcripts as putative targets per guide
strand.7 Thus, target recognition following RISC binding sequesters
and represses RNA translation. In mammals, only Argonaute 2
(AGO2) possesses the so-called “Slicer” capacity to cleave its tar-
gets,8,9 an endonuclease function that generates a novel, uncapped
50 end on RNA, preventing transcript translation and enabling target
RNA degradation.10 Importantly, slicing is principally focused oppo-
site positions 10–11 from the 50 end of the guide strand11,12 and seems
to require full Watson-Crick base pairing across these bases.13 Thus,
detecting a novel 50 end on an RNA target at this location provides
explicit evidence of an on-target mechanism of action for Slicer
RNAi. Together with the seed sequence, these two features have pre-
occupied mechanistic studies of novel RNAi therapeutics.14
Historically, the low-resolution 50 RNA ligase-mediated rapid ampli-
ﬁcation of cDNA ends (50 RLM-RACE)15 method has been used to
provide qualitative evidence of the mechanism of action of Slicer
RNAi.16,17 More recently, medium- and high-resolution quantitative
methods, such as next-generation sequencing of total RNA (RNA-
SEQ) and 50 RLM-RACE products (RACE-SEQ),18,19 respectively,
have been developed. Importantly, the high resolution of RACE-
SEQ has conﬁrmed that slicing of a given target can be considerably
less precise than originally thought. Thus, up to a quarter of all Slicer
cleavage products generated by a single guide strandmight occur even
as many as +5 bases further away from the primary cleavage site,
toward the 50 end of the RNA target molecule.18 Although slicinge Authors.
ecommons.org/licenses/by/4.0/).
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Figure 1. Using RNA Replicon Systems and RACE-SEQ to Query and Enumerate the Susceptibility of Target Mismatches to Defined RNAi Mediators in a
Patient-free, Agnostic, and Minimally Biased Manner
(A) Slicing of a given RNA target (e.g., the RNA genome of HCV) generates novel 50 ends at a primary cut site, principally opposite positions 10–11 from the 50 end of guide
strand loaded onto an AGO2-RISC. (B) The 50 RACE-SEQ assay uses a gene-specific primer positioned downstream of the cut site on a target RNA to digitally report both the
primary and additional fragments generated (e.g., degradation products starting to the right of the cleavage site or other guide strand-induced fragments starting beyond the
Slicer primary active site). Due to HCV’s high mutation rates, various polymorphisms (indicated by “X”) result in multiple quasi-species of virus arising within the context of a
single viral genotype. We thus explore how random and specific mismatches in a given target affect RACE-SEQ outputs, to map how target variability affects Slicer
susceptibility semiquantitatively and in a base-by-base manner.
www.moleculartherapy.orgimprecision was previously observed after Sanger sequencing of
50 RLM-RACE products,20,21 research has focused on minimizing
the off-target effects of RISC in terms of unintended transcript
engagement (e.g., due to seed-mediated target recognition).22 The
impact of target variability beyond single nucleotide polymorphisms
(SNPs),23 heterozygocity,24 or mutational escape in RNAi-targeted
viruses25 remains unexplored.
The original description of RACE-SEQ involved synthetic, short
interfering RNA (siRNA) mediators of RNAi targeting hepatitis
C virus (HCV), as modeled in a well-established, in vitro HCV
RNA replicon system.18 HCV is a positive RNA strand virus that
encodes an RNA-dependent RNA polymerase (RdRP) required for
the replication of the viral genome.26,27 This enzyme, which is also
used for replicon maintenance in vitro, lacks any proofreading func-
tion,28,29 making HCV replication highly error prone.30,31 As a result,
it is common to detect populations of HCV genome sequences within
single viral genotype infections, even when using Sanger sequencing;
these are referred to as HCV quasi-species.32 However, unlike the
restricted sequence variability of host transcripts because of low
somatic mutation rates,33 the inherent genomic variability of HCV
presents a unique opportunity to study how mismatches arising
randomly on targets may affect the speciﬁcity of Slicer.
Thus, in their original study, Denise et al.18 used unmodiﬁed siRNA
analogs of the principally active guide strands processed out of the
ﬁrst-in-class biotherapeutic RNAi drug TT-034. This proposedsingle-shot treatment for HCV is an adeno-associated virus 8 gene
therapy that targets hepatocytes to express three short hairpin RNA
(shRNA) mediators of RNAi designed to cleave the HCV RNA
genome.34 The authors used sub-maximal (30 nM) concentrations
of these three siRNAs, independently reverse transfected into
Huh7.5 cells harboring a HCV replicon. At 48 hr, RNAwas harvested,
subjected to 50 RLM-RACE using a shortened 50 RNA adaptor,
strand-speciﬁc gene-speciﬁc primers, and touch-down PCR, to yield
85-base pair (bp) amplicons. The amplicons were then subjected
to Illumina deep sequencing in a paired-end fashion; due to their
short size, these amplicons were thus subjected to high-accuracy
duplex sequencing.35 Novel 50 ends were enumerated after adaptor
trimming and alignment to the reference replicon genome using a
proprietary bioinformatic pipeline. We postulated that stringent
data mining of such RACE-SEQ datasets could yield additional valu-
able information: the highly variable nature of the HCV genome
should enable querying of Slicer precision against HCV quasi-species
targets with one or more mutations natively found in these datasets.
In addition, by carefully controlling mismatch tolerance during SEQ
data alignment, we should be able to examine cleavage activity on the
HCV quasi-species in a base-by-base manner (Figure 1).
Here, we therefore expand upon the siRNA RACE-SEQ data gener-
ated by Denise et al.18 to explore the susceptibility of the HCV repli-
con quasi-species to the three guide strands principally produced by
TT-034. We demonstrate how the speciﬁcity and relative potency of
RNAi mediators against all possible variants of a target sequence canMolecular Therapy: Nucleic Acids Vol. 9 December 2017 23
Figure 2. The Open-Access Bioinformatics Pipeline
for Low Computational Overhead RACE-SEQ
Analysis, Including Exploration of Mismatch
Tolerance and Mismatched Target Recognition by
Slicer RNAi
Molecular Therapy: Nucleic Acidsbe determined agnostically and in a minimally biased manner, at the
single nucleotide level, simply by using replicon systems. Moreover,
we present a low computational overhead pipeline freely available
online under the GNU General Public License for the processing of
RACE-SEQ data (Figure 2), and we provide simple pipeline adjust-
ments for evaluating the tolerances of an RNAi therapeutic to target
sequence variation.
RESULTS
Low Computational Overhead Data Processing
The high processing speed and memory efﬁciency of the Cutadapt
package is ideal for implementation in RACE-SEQ analyses due to
its ability to deﬁne RACE adaptor location (50 or 30), thereby enabling
more precise trimming. This means our pipeline is also easily imple-
mentable in 30 RACE-SEQ studies (e.g., to understand cleaved RNA
degradation in a 30/50 manner). To maintain 100% complemen-
tarity with the adaptor and consistency with Denise et al.,18 Cutadapt
was set to “-e0 –no-indels –discard-untrimmed.” Thus, all accepted
reads would contain the exact 50 RACE adaptor sequence used exper-
imentally and no other RNA ligation products (Table S1). In addition,
FastQC conﬁrmed that all the adaptor-trimmed reads had quality
scores well within the normal distribution and sequence lengths of
between 45 and 50 bps trimmed off a 85-bp read containing a
30-nt RNA adaptor (Figure S1). Furthermore, collapsing the datasets
with fastx_collapser into ﬁles enumerating read incidence also signif-
icantly reduced data complexity. This illuminated the variety and
prevalence of the Slicer products generated. Thus, only 1,644 different
sequences made up for the 2.5 million reads that aligned to the HCV
replicon genome (GenBank: AJ238799) using Bowtie1, representing
78.15% of the dataset. In stark contrast, 298,000 different sequences
corresponded to apparently non-HCV data (Table 1). This meant
that the 2-log reduction of reads due to collapsing could be
extended by another 2 logs simply by removing the highly diverse
read dataset that did not align to HCV, ultimately reducing the
12.5-GB initial dataset ﬁles to 18.5 MB. Crucially, despite the drastic
reduction in ﬁle size, enumeration of novel 50 ends did not introduce
any appreciable artifacts relative to the scale of the novel 50 end count
dataset (Figure 3).
On the other hand, given the signiﬁcant size (21.9%) of apparently
unaligned reads within the dataset (5.7M; Table 1), the unaligned24 Molecular Therapy: Nucleic Acids Vol. 9 December 2017data fraction was collapsed and compared to
the HCV replicon genome bymultiple sequence
alignment. This analysis revealed that 28.1% of
the unaligned dataset contained sequences with
minimal variation (e.g., mismatches, indels) to
the HCV reference genome (Figure S1). Giventhe error rate of HCV’s RdRP and the relative size of this HCV-related
read population, this data subset was interpreted as a sequencing
signature of the HCV quasi-species within the 50 RACE-SEQ data.
Thus, re-aligning the reads against the HCV replicon, this time ac-
cepting up to 3 mismatches to the replicon reference sequence, indi-
cated that up to an additional 1.6M reads might indeed arise from
naturally occurring HCV replicon variants.
Replicon Quasi-species Are Also Cleaved by Slicer
We next proceeded to examine in detail the impact of tolerating
mismatches to the 50 RACE-SEQ proﬁle. To begin with, we aligned
the 50 RACE-SEQ reads to the HCV replicon reference genome,
conﬁguring Bowtie1 to tolerate an increasing number of randommis-
matches; the results were then plotted as the increase in novel 50 end
counts for each additional mismatch tolerated (Figure S2). This indi-
cated that the overall cleavage proﬁles were not affected for siRNA19
and siRNA22. Thus, with position 10–11 remaining the primary
cleavage point, the relative proportions of novel 50 ends among mis-
matched reads generally followed the same trends as those of fully
aligned reads, whether one, two, or three mismatches were tolerated.
On the other hand, with siRNA6, substantially more novel 50 end
counts were observed downstream of the cleavage site: curiously, in
some cases, the mismatch-containing reads were well in excess of
counts obtained in the absence of mismatches, making the total num-
ber of siRNA6 cleavage events 234 higher than that observed for
siRNA19. At ﬁrst glance, these results raised the prospect of extensive
quasi-species sequence variability within the siRNA6 hybridization
site, against which siRNA6 might be more active. However, we
considered this highly unlikely for three reasons. First, the siRNA6
target site lies within the IIId domain of the 50 non-coding region
of HCV, a highly structured RNA conserved across HCV genotypes36
and even into picornaviruses.37 Second, historical in vitro38 and
in vivo39 data with a semiquantitative RT-PCR assay indicated an
overall siRNA6 activity level lower than that of siRNA19. Third, reads
starting downstream of an siRNA primary cleavage point, shorter by
10 nt, would be expected to exhibit an increased likelihood of type I
error (false positive alignments) with increasing mismatch tolerance.
Furthermore, looking at the log-scale differences in total novel 50 end
counts between the three siRNAs (103 for siRNA6 versus 107 for
Table 1. Effect of Read Collapsing on Read Count and Reference Alignment
with No Mismatches Tolerated
Reads
Before Collapsing After Collapsing
Absolute Relative (%) Absolute Relative (%)
Aligned to HCV 20,505,001 78.15 1,644 0.55
Unaligned 5,733,712 21.85 297,932 99.45
Total 26,238,713 100.00 299,576 100.00
www.moleculartherapy.orgsiRNA22), we considered the value of normalizing the mismatched
alignment counts for the amount of data available per position. To
do this, we plotted the cumulative log-scale differences in novel
50 end counts at increasing levels of mismatch tolerance (Figure S2).
This analysis highlighted how the novel 50 end count increases across
the shorter G1–G6 reads of the siRNA6 hybridization site increased
alongside the extent of mismatching permitted. No substantial
(>10) differences were observed across the siRNA6 central or
upstream region, nor indeed across the entirety of the siRNA19
hybridization site. Interestingly, in the largest dataset by read depth
(siRNA22; Figure 4), a nearly 1,000 increase was observed in novel
50 ends at position C17 from the 50 end of siRNA22. In contrast to
C17, increases at position A13 seemed to reﬂect the extent of
mismatch tolerance permitted. Taken together, these results reaf-
ﬁrmed the value of considering 50 RACE-SEQ data in log scale (i.e.,
similar to RNA-SEQ). Furthermore, they indicated that mining repli-
con quasi-species susceptibility throughmismatch tolerance would be
more robust for longer 50 RACE-SEQ reads. Thus, as little as a single
mismatch could be shown to potentiate cleavages beyond the primary
Slicer site, such as at position C17 in the siRNA22 hybridization site.
However, as this effort did not shed light on where these mismatches
might be located, we decided to explore how each possible base
substitution in the siRNA22 hybridization site affected the ensuing
novel 50 end proﬁle.
Replicon Quasi-species Analysis Distinguishes Polymorphic
Targets Subject to RNAi-Directed Cleavage
To achieve this using Bowtie1, we used anR script and carried out iter-
ative alignments with -v set to 0 against a set of HCV replicon refer-
ence genome variants manually derived from GenBank: AJ238799.
These were produced to cover all possible SNPs within the siRNA hy-
bridization site seed sequence (Figure 5) and the central, Slicer active
site-spanning region (Figure 6). Thus, each of these 36 alternative
reference genomes would feature one of three possible substitutions
at a speciﬁc position within the siRNA binding site (e.g., in siRNA22,
10T to 10A, or 10C or 10G; Figure 6B), and novel 50 ends would be
accepted only when reads were fully complementary to the speciﬁc
SNP-containing genome. To allow direct comparisons of the effect
of each polymorphism on novel 50 end proﬁles, we overlaid the three
alternative proﬁles as color-coded line graphs against the wild-type
histogram proﬁle, highlighting the substitution position on the x axis.
As expected, novel 50 read counts downstream of the base substitution
were not affected (Figures 5 and 6; gray bars), as these reads did notinclude the substituted base. However, remarkable and variable
differences in novel 50 end counts were observed upstream (i.e., when
incorporatingbase substitutions in read alignment).Crucially, substitu-
tions at position 10 reduced Slicer activity by 3 (10T/C or A) or
4 logs (10T/G) but did not eliminate it. Moreover, the 3-log increase
in read counts at C17 observed under random mismatch analysis was
identiﬁed as an A13/G polymorphism.
DISCUSSION
Since its inception, RACE-SEQ has been used by others17,19,40 to
enhance evidence of RISC-mediated target cleavage precision in prep-
aration for pre-clinical and clinical studies. Two rate-limiting factors
in the wider adoption of the method have been cost, associated with
sequencing depth requirements, and the complexity of data process-
ing. As we progress the method to medium-throughput deep
sequencer compatibility (e.g., Illumina MiSeq and the Ion Torrent
Personal Genome Machine) for reliable routine use, here we present
a simple and computationally lean approach to RACE-SEQ data
handling and representation. The resulting “RACE-SEQ lite” pipeline
reduces raw data size by 4 logs and enables wider technique adop-
tion by the community. This is illustrated by the computational anal-
ysis of the data presented in this article, which was performed on a
dual core, 4-GB RAM laptop with a 250-GB hard drive: simple
RACE-SEQ analysis to 50 incidence graph production took approxi-
mately 20 min from a 12.5-GB .fastq ﬁle, while the 36 reference
genome alignment and mismatch tolerance analyses took 9.6 hr to
process. In developing this “RACE-SEQ lite” pipeline, we also took
the opportunity to explore how sequence variability in RISC targets,
as opposed to guide strand engineering, drives the mismatch toler-
ance of siRNAs. In this sense, data from RNAi applied on a
HCV-based RNA replicon system were ideal: the well-documented
error-prone replication of HCV naturally gives rise to sequence vari-
ance within the intended RNAi target. One could therefore explore
the effects of this variance simply by actively looking for mismatches
within the RACE-SEQ data. Such an extent of sequence variability is
not normally easy to study with transcripts encoded in a DNA
genome. However, this kind of analysis is useful because it permits
the preemptive minimally-biased study of the impact of any possible
polymorphism to the efﬁcacy of RNAi treatment.
We therefore initially explored how tolerating random mismatches
during read alignment would inﬂuence the incidence of novel
50 ends generated on siRNA target regions. We reasoned that
sequencing error would result in increases randomly distributed
across the entire siRNA target site and would thus have no effect
on overall cleavage proﬁles. In addition, smaller RNA fragments ter-
minating proximally to the guide strand 50 end would be also expected
to randomly align to the reference genome as the number of mis-
matches tolerated was increased. While this indeed was the case for
siRNA6 and siRNA19, analysis revealed positions 13 and 17 from
the 50 end of the siRNA22 guide strand as interesting exceptions (Fig-
ure 4). Crucially, the number of novel 50 ends increased by3 logs at
position 17 irrespective of the number of mismatches tolerated. In
contrast, the number of 50 ends starting at position 13 increased inMolecular Therapy: Nucleic Acids Vol. 9 December 2017 25
A B C
Figure 3. Effect of RACE-SEQ Data Processing Using a Proprietary High Computational Overhead Pipeline versus the Newer Pipeline Presented Herein for
Three Separate siRNAs
(A–C) siRNA6 (A), siRNA19 (B), and siRNA22 (C) target independent sites on the HCV replicon genome. Driving Slicer-mediated cleavage of the HCV replicon RNA genome
suggests less than 0.001% variance to maximal incidence counts. Changes in novel 50 read counts (y axis) at each position on the HCV genome targeted by an siRNA (x axis;
HCV genome in a 50 to 30 fashion) is represented in log10 scale reflecting the data distribution range for 50 end incidence counts.
Molecular Therapy: Nucleic Acidsline with the extent of mismatch tolerance. This difference indicated
that the observation at position 17 was unlikely to be an artifact of
aligner tuning, but an indicator of an alternative cleavage site at
this position, found exclusively among replicon sequence variants
with one or more mismatches to siRNA22. Curiously, these new
read counts at position 17 were comparable to observations across
positions 14–17 in the absence of mismatches (Figure 5). Thus, it
appears that the activity of siRNA22 in this area might be consistent
whether targets have none, 1, 2, or 3 mismatches to the siRNA, and
that this activity is 3–4 logs lower than that normally observed at
position 10–11.
Importantly, this evidence builds upon the observation of Denise
et al.18 that up to 25% of all novel 50 ends produced by siRNA19
occurred across positions 11–15, a range that partially overlaps
with positions 14–17 in the siRNA22 target site. It is therefore not sur-
prising that mismatch tolerance analysis of the siRNA19 RACE-SEQ
dataset revealed no new or substantially enhanced cleavage points
across positions 14–17 (Figure S3). However, together with the
siRNA22 mismatched read data, it would appear that cleavage within
14–17 can vary by as much as 4 logs. Whether a secondary cleavage
site also exists in siRNA6 in this region is presently unknown, prob-
ably because of the low, 3-log dynamic range in this dataset on ac-
count of lower sequencing depth. Indeed, all of the novel 50 ends in
the siRNA6 target site revealed through mismatch analysis depended
on the extent of mismatching permitted (Figure S4). Moreover, pipe-
line comparisons (Figure 3) suggested the siRNA6 dataset to be less
resilient, a common indicator of inadequate sequencing depth. On
this basis, we would argue that at least 10M 50 RACE-SEQ reads
are required per RISC target site to determine reliably both on- and
off-target Slicer activity. Importantly, this is consistent with evidence
from systematic studies on minor variant detection for HCV using
next-generation sequencing.41
Nevertheless, the data for siRNA19 and siRNA22 implicate positions
14–17 as the putative focal point for a potentially secondary slicing26 Molecular Therapy: Nucleic Acids Vol. 9 December 2017site, which can be potentiated by as little as a single mismatch.
Notably, such observations have also been reported by others, beyond
HCV replicon systems, in vivo, against endogenous targets. Thus, Ga-
nesh et al.19 reported evidence of <5% incidence of novel 50 ends at
position 14 for at least two of the ﬁve mice treated with a DICER-sub-
strate siRNA. Whether lower-level activity was also present among
the remaining animals remains unclear due to percentile data scaling
in the report by Ganesh et al. and lack of clarity on coverage of the
slicing site. Interestingly, this putative secondary Slicer active site
spanning positions 14–17 of the guide strand is in accordance with
the transitional nucleation model42 that favors a 30 end guide strand
interaction around positions 13–16 through restricted seed sequence
engagement. More importantly, it permits for guide strand-to-target
interaction slippage, which could account for observations of impre-
cise Slicer-mediated action upstream of position 10–11. Put simply,
the 30 end guide strand interaction model could account for Slicer-
mediated cleavage induction across positions 13–16 with lower afﬁn-
ity to the canonical model, or RISC loading driven by guide strand
slippage and not by Slicer imprecision. It is unclear at present, how-
ever, to what extent the stability of the RNA cleavage products arising
at this position confounds the pinpointing of a putative secondary
Slicer active site suggested through RACE-SEQ. In other words, the
primary novel 50 end peak in this region may shift to the right simply
because of exonuclease activity.
A simpler interpretation of our observations would be evidence of
RNA destabilization achieved by non-Slicer Argonaute RISC activity.
However, this is incompatible with the 30 end de-adenylation or
50 end de-capping and 50/30 degradation mechanism proposed for
endogenous transcripts.42 HCV and its replicon systems lack a
50 cap43 or a poly(A) tail and rely on RISC complexes to promote their
stability.44 Alternatively, RISC recruitment to sites other than the
microRNA-122 recognition elements on the HCV genome44 could
disturb the protective mechanism of microRNA-122 either directly
or via Argonaute sequestration, thereby permitting replicon degrada-
tion by the RISC-associating exonucleases XRN-1 and XRN-2,45,46 in
A B C
Figure 4. Impact of Increasing Random Mismatch Tolerance in siRNA22 RACE-SEQ Reads upon Bowtie1 Alignment to the HCV Genome
(A–C) The effect of 1 (A), 2 (B), or 3 (C) random mismatches in read alignment is expressed as the increase in novel 50 ends (y axis) generated at a given position of the HCV
genome (x axis), revealing position 13 (white arrow), but not position 17 (black arrow), variability to be dependent on mismatch tolerance extent.
www.moleculartherapy.orgaddition to Slicer activity on the siRNA target site. The present data,
however, do not support this hypothesis: treatment with control
siRNAs would have resulted in de-protection of the replicon and
RACE-SEQ-mediated detection of these secondary sites but not the
Slicer site at position 10–11. Instead, we detected cleavages with the
siRNA target sites in the control samples used by Denise et al.18
only when we accepted one or more mismatches during read align-
ment. Importantly, these occurred randomly across the target site
and increased alongside the number of mismatches tolerated, suggest-
ing nothing more than sequencing or mismatched alignment artifacts.
With random mismatch tolerance evidencing what we interpreted as
additional RNAi activity onto the HCV replicon quasi-species, we
next set out to map the effects of speciﬁc mismatches on Slicer func-
tion as reported by RACE-SEQ, speciﬁcally in siRNA22. To do this,
we plotted the effects of all possible nucleotide substitutions across
the seed region (Figure 5), and the primary Slicer cleavage site (Fig-
ure 6), in terms of novel 50 incidence on the siRNA22 target site, as
reported by the same RACE-SEQ biological dataset produced by De-
nise et al.18 Interestingly, forcing speciﬁc mutations in the reference
sequence resulted in as much as a 4-log decrease in the number
of novel 50 ends (e.g., at position 10–11). This was consistent with
the changes enumerated by accepting random single mismatches
on novel 50 end counts (Figure 4). Closer examination indicated
that mismatches within the seed region exerted a substantial effect
on siRNA Slicer activity, but did not eliminate it (Figure 5): cleavage
at position 10–11 remained the primary activity of Slicer RISC as
enumerated by RACE-SEQ. Nevertheless, the substantial silencing
potential demonstrated through this analysis, even when >1 polymor-
phism/mutation arises within a guide strand hybridization site, may
explain why resistance evolution studies with RNA viruses often
report stabilizing mutations beyond the RISC binding site.
Looking at the relative impact of different mismatches, the effect of
speciﬁc base substitutions within a deﬁned position was either negli-
gible, or no more than 1.5 logs, and was more pronounced for
positions 2–4 in the seed region (Figures 5A–5C). Here, A/T trans-versions at positions 2 and 3 and C/G at position 4 had the strongest
effect, indicating that M/K transversions at these locations may
reduce cleavage at the primary active site of Slicer. The effect of
mismatches at position 5 appeared less sensitive to speciﬁc types of
substitutions (Figure 5D), expanding on previous observations
regarding the effect of a G:U wobble in the context of otherwise full
complementarity between miRNA-196 and HOXB8.47 However, we
noted that a C/G transversion at this position eliminated novel
50 generation at position 5, with a C/K transversion affecting novel
50 end generation at positions 6 and 7 too. Similarly, A/Y transver-
sions at position 3 eliminated novel 50 end detection at position 7,
whereas A/G transition only reduced counts by 1 log. These ob-
servations point away from cytosolic adenosine deaminase activity48
or exonuclease activity on fragments generated by cleavage at position
10–11 and in the direction of transversions in overcoming RNAi-
induced target restriction. Thus, given the known preference of RNase
A for YpR and Yn stretches,
49 one would expect changes that would
increase RNase A susceptibility across the Y-rich 3-7 region to consis-
tently reduce the incidence of novel 50 ends. However, this is promi-
nently not the case, as 4C/G and 5C/G also drop read counts.
These results may therefore indicate Slicer slippage toward the
50 end of the guide strand in addition to 30 end slippage proposed
by Denise et al.,18 and they suggest that off-target transcripts with
seed sequence transversions might be less susceptible to RISC recog-
nition. Alternatively, cytosolic RNase activity engaged in Slicer
product decay (XRN enzymes45,46) might be responsible for these ob-
servations. However, as the substrate preferences of these enzymes are
not as well understood, and the shorter 50 RACE-SEQ reads generated
in this region might be misleading as observed for siRNA6, additional
scrutiny is necessary before making conclusive statements over the
slippage reach of Slicer or off-target transcript prediction.
Nevertheless, it is noteworthy that our observations are in agreement
with a recent report by Geller et al.50 on the role transversions may
play in HCV drug resistance evolution. Thus, both reports highlight
an overrepresentation of A/G and U/C transitions in HCV repli-
cons. Crucially, like Denise et al.,18 Geller et al.50 used bi-directionalMolecular Therapy: Nucleic Acids Vol. 9 December 2017 27
A B C
FED
Figure 5. Effect of Specific Nucleotide Substitutions across from the Seed Region of siRNA22 on Novel 50 End Generation in the Genome of a HCV Replicon
(A–F) The specific substitution within the seed region [position 2 (A) to position 7 (F) in a 50 to 30 direction for siRNA22; i.e., right to left] is highlighted by the boxed nucleotide on
the x axis of each panel. Scissors highlight the Slicer primary active site. Bar plots depict the cleavage profile generated in the wild-type Con1B HCV replicon reference
sequence. A differentially colored line represents the effect of each possible base substitution within the boxed base. Reads starting at positions downstream (to the right) of
the iteratively substituted nucleotide (box) are not affected by substitutions and therefore have no effect on novel 50 end counts (shaded barplots), resulting in overlapping
substitution effect lines.
Molecular Therapy: Nucleic Acidssequencing (duplex sequencing)35 to reduce the Illumina per-base
read error rate in their studies to 8.4  108. Thus, Denise et al.18
adopted pair end sequencing over 85-bp RACE amplicons with
no interspersed sequences between the paired reads, effectively
applying what was later coined as duplex sequencing35 to the
50 RLM-RACE amplicons. Interestingly, this error rate also matches
the number of relevant RNA templates available to 50 RACE-SEQ
enumeration. Accordingly, the data discussed herein were produced
from 96-well experiments seeded with 20,000 cells, each containing
40,000 copies of the Con1B replicon RNA (>8 108 RNA templates
total), the sum of which was subjected to 50 RACE-SEQ. On this basis,
we believe a 10-read (1 log10) threshold is justiﬁable across the 8-log10
read dynamic range of the Denise et al.18 dataset. Importantly, Geller
et al.50 also evaluated the per-base mutation frequency for HCV repli-
cons: the target site mutation frequency of siRNA22 (Figure S7) aver-
aged 1.97  104 ± 9.72  105 in their study and reported minimal
variance between replicon lines. This mutation frequency is consis-
tent with our hypothesis that the assay data comfortably sample
quasi-species sequences and are comparable to the novel 50 end
counts obtained (e.g., at mismatched 10T for siRNA22). It also sug-
gests that detecting dual or triple mutant variants (2–3 mismatches)
will be difﬁcult, thereby constraining quasi-species analysis to reads
containing only a single mismatch. Moreover, the 1.97 104 muta-28 Molecular Therapy: Nucleic Acids Vol. 9 December 2017tion frequency deﬁned by Geller et al.50 is practically identical to the
previously empirically derived, 20,000 coverage recommendation
for minor variant detection in HCV-infected patients.41 It follows
therefore that per-base coverage would need to substantially exceed
2  104 to allow for reliable and quantitative detection of quasi-spe-
cies variants within 50 RACE-SEQ data. Indeed, coverage across the
target site of siRNA22 spans 2.70  104- to 2.22  107-fold (Fig-
ure S7), with the 50 end sensitivity of the RACE-SEQ assay and the
dominance of Slicer fragments starting at position 10–11 explaining
the 3-log10 coverage range. Most notably, where RACE-SEQ data
coverage exceeds the per-base mutation frequency identiﬁed by Geller
et al.50 threshold by more than 3 orders of magnitude, novel 50 ends in
quasi-species variants involving a speciﬁc single base substitution are
comfortably detectable, even at coverages approaching 10,000 (e.g.,
Figure 5C). Taken together, these parameters strongly suggest that
our observations regarding speciﬁc base substitutions are not the
result of sequencing errors, but a true representation of the combined
relative incidence of replicon quasi-species with a single base substi-
tution within the speciﬁc siRNA target sites, and their individual
susceptibility to Slicer cleavage.
Beyond the seed region and primary cleavage point, mismatches
across positions 2–3 were not restrictive upon the secondary
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Figure 6. Effect ofSpecificNucleotideSubstitutions across from theSlicerActiveSite for siRNA22 onNovel 50 EndGeneration in theGenomeof aHCVReplicon
(A–F) A boxed nucleotide on the x axis highlights the base substituted within each panel across the Slicer active site (scissors) between position 9 (A) and position 14 (F) in a
50 to 30 direction of siRNA22 (i.e., right to left). Bar plots depict the cleavage profile generated in the wild-type Con1B HCV replicon reference sequence. A differentially colored
line represents the effect of each possible base substitution within the boxed base. Reads starting at positions downstream (to the right) of the iteratively substituted
nucleotide (box) are not affected by substitutions and therefore have no effect on novel 50 end counts (shaded barplots), resulting in overlapping substitution effect lines. The
source of the C17 novel 50 end count increases identified in Figure 4A is highlighted by the black arrow.
www.moleculartherapy.orgcleavage point(s) detected closer to the 30 end of the hybridization
site of the siRNA (positions 11 and beyond). However, we observed
the opposite effect as we began forcing mismatches closer to the pri-
mary active site of Slicer (position 5 onward; Figures 5D–5F). This
culminated with substitutions at positions 10–12 (Figure 6), suggest-
ing that hybridization across the center of the guide strand and
target is essential for cleavages to occur across positions 14–17,
whatever the underlying mechanism(s) might be. The most unex-
pected ﬁnding, however, was that substitutions at position 10 did
not eliminate novel 50 end generation, but reduced it only by 3–5
logs (Figure 6B). This ﬁnding has important implications on the
relative activity of allele-speciﬁc RNAi and, indeed, other similar
oligonucleotide therapeutics. Thus, allele-speciﬁc RNAi51 involves
guide strands designed against deleterious alleles in heterozygous
cells wherein imprinting is not involved in selective allele expression
and pivots on differential complementarity across the primary
slicing site between the two alleles. As a result, mutant transcripts
are sliced, permitting wild-type alleles to restore a healthy pheno-
type. Our evidence of cleavage even on transcripts mismatched at
positions 10 and 11, however, suggests that the selectivity of allele-
speciﬁc RNAi will more likely depend on classical enzyme kinetics:
substrate concentration and afﬁnity (RISC substrate on-rates, slicer
cleavage rates, and RISC product off-rates). Thus, slicing of the
healthy, mismatched allele transcript will occur and increase whenits concentration exceeds the substrate dominance of the mutant
transcript (e.g., due to epigenetic expression regulation or homeo-
static factors relating to cellular phenotype, feedback loops, etc.).
Consequently, the kinetics of Slicer selectivity against mismatched
targets become increasingly less relevant in an allele-speciﬁc RNAi
therapeutics context, as the balance and concentration of mutant
versus wild-type transcripts feeding cellular translational machinery
is disrupted. Notably, the principle of slicer-speciﬁc RNAi has been
developed using overexpression systems and saturating concentra-
tions of siRNAs, which are both far removed from physiologically
relevant concentrations of RNA targets or indeed siRNA drugs. It
is important at this point, however, to highlight that the understand-
ing of target engagement kinetics in a RISC complex in isolation52
and in conjunction with its associated co-factors is too nascent to
directly relate to the simplistic two-state model or even nearest-
neighbor model of melting temperature (Tm) calculation. Thus,
while calculating a free-solution DTm for the polymorphic targets
might be simple, neither approach takes into account the allosteric
effects of the RISC complex to target engagement, nor are the sub-
cellular concentrations of key ionic solutes known or indeed stable.
The net effect is that it is unclear at this point if a free-solution
Tm value, whether computed or experimentally derived, effectively
relates to the physiological conditions pertaining to RISC-substrate
engagement and its preference to speciﬁc mismatches. Indeed, theMolecular Therapy: Nucleic Acids Vol. 9 December 2017 29
Molecular Therapy: Nucleic Acidsposition-speciﬁc tolerances to mismatched substrates demonstrated
with miRNA and herein (e.g., position 5) point away from this
precept.
On the other hand, a C/A transversion at position 11 resulted in
only <1 log effect on novel 50 ends starting at this position or position
12, identifying again a M/K substitution as detrimental (>3 log
reduction onto elimination) to target recognition (Figure 6C). In stark
contrast, any substitution at position 12 practically eliminated cleav-
ages within the 30 end of the hybridization site (Figure 6D). Crucially,
as we report that cleavage beyond position 12 necessitates full
complementarity across the central region of the guide strand, the
requirement effectively locks in tandem the two CTCA runs in the
siRNA22 guide strand hybridized to the target sequence. This would
suggest that cleavages beyond the primary AGO2 active site are not
on account of guide strand slippage, and they are a consequence of
either AGO2 slippage around the guide strand-to-target duplex or a
secondary enzymatically active site in AGO2. Alternatively, the lower
50 RACE-SEQ coverage across positions 14–17, where the secondary
CTCA run resides, may occlude slicing events among the replicon
quasi-species. Attempting sequencing at this depth would be prob-
lematic, as this would compromise the ultra-low error rate of dual
sequencing, whereas physical separation of the secondary cleavage
products would be challenging due to the minimal size differences
of the amplicons. Nonetheless, for the central CTCA run to slip up-
stream on the target and drive slicing, practically the entire 50 end
(5 of 7 bases) and 30 end (4 of 9 bases) would need to be mismatched
to the target (9 of 19 mismatches total). On balance, the bulk of
evidence over mismatch tolerance to date,3 the observation of cleav-
age around positions 14–17 with siRNA19, which lacks any sequence
repeats in this region, and the data of others implementing 50 RACE-
SEQ19 would argue against such a hypothesis and favor AGO2-driven
secondary site cleavage as the most likely mechanism.
Notwithstanding such additional behaviors by AGO2, we propose
that future studies on therapeutic siRNAs and indeed other endonu-
cleotically active oligonucleotide therapeutics may ﬁnd considerable
value in pursuing RACE-SEQ analysis of partial or, preferably, full-
length target transcripts incorporated within replicon systems.
Capturing the detailed effects of speciﬁc base substitutions in such
a semiquantitative manner may inform more precise off-target gene
identiﬁcation (e.g., by actively looking for target sequence-dependent,
position-speciﬁc tolerances). We would also argue that inclusion of
more than just the RISC hybridization site would be relevant in
ensuring best possible maintenance of the structural sequence
context, as suggested previously regarding microRNA recognition
element reporter systems.53 Alternatively, exploring base-by-base
variant susceptibility through RACE-SEQ on a replicon system may
inform the extent to which known and unknown genomic polymor-
phisms in the population are susceptible to RNAi and antisense drugs.
Thus, patient stratiﬁcation and theranostic potential, an element of
personalized cancer medicine increasingly required for new drug
approval,54 would normally require the labor-intensive construction
of reporter plasmid libraries encompassing the most common muta-30 Molecular Therapy: Nucleic Acids Vol. 9 December 2017tions among a patient population. This would rely on public domain
information on polymorphism incidence, which is inherently biased
by the limitations in population sampling encountered during data-
base construction (e.g., dbSNP) and is compounded by researchers’
propensity to explore the effects of only the most common SNPs.
In contrast, replicon construction is a relatively simple, single plasmid
engineering process that substantially de-risks this bias, as it does not
depend on patients, albeit with a tendency to prefer transversions to
transitions. Thus, as we show here, all possible SNPs can be semi-
quantitatively analyzed for their susceptibility to a given RNA-acting
drug through RNA-SEQ, in a minimally biased fashion, to pre-emp-
tively inform clinical trial patient selection and, ultimately, drug
prescription, thereby maximizing the chances of achieving a thera-
peutic effect. Conversely, the method may offer value in monitoring
the mutational escape propensity of tumors, quantifying in a mecha-
nism-of-action-dependent way the impact of speciﬁc mutations
within a target sequence.
In summary, by implementing advances in SEQ data handling, we
present a relatively simple, open-access pipeline for RACE-SEQ
data processing. Moreover, we advance the approach to using repli-
con systems for exploring in detail how target mismatches to guide
strands affect RNAi-mediated target cleavage. Furthermore, our
data offer additional insights on the roles of seed and primary cleav-
age point base pairing for both canonical Slicer activity at position
10–11 as well as what appears to be secondary Slicer activity (Slicer
slippage) closer to the 30 end of the guide strand. By using a natively
error-prone RNA replicon system, we were also able to scrutinize base
by base how substitutions in a target affect its recognition by RISC.
This approach may signiﬁcantly empower a priori drug susceptibility
research for emerging RNA-targeting therapeutics. Thus, using this
patient-free, bench-based, and minimally biased method, semiquan-
titative data can be produced to inform patient selection in clinical tri-
als. Moreover, we show how mismatches, even within the primary
Slicer active site, can still give rise to novel 50 ends toward the
30 end of the guide strand and perhaps even within the seed region.
Whether these actions are driven by AGO2 or emerging co-factors
such as GIGYF255 remains to be determined.
MATERIALS AND METHODS
Datasets
We revisited all three RACE-SEQ datasets originally reported by De-
nise et al.18 Each of these datasets corresponds to the Slicer products
generated on the HCVCon1B genome pFK I389 Lucubineo EI NS3-30
ET (GenBank: AJ238799) by synthetic analogs of the three primary
siRNAs expressed by TT-034, siRNA6, siRNA19, and siRNA22.
The target region of siRNA6 (50-CGAAAGGCCTTGTGG
TACTG-30) is located in the 50 UTR on position 272–291, whereas
the target regions of siRNA19 (50-GTCAATTCCTGGCTAGGCA
ACAT-30) and siRNA22 (50-CAAGCTCAAACTCACTCCAAT-30)
are located in the NS5B gene, which codes for the viral RNA-depen-
dent RNA polymerase, on positions 9,095–9,117 and 9,478–9,498,
respectively. Brieﬂy, we used Illumina reads supplied as individual
.fastq ﬁles after sequencing adaptor and quality-control trimming.
www.moleculartherapy.orgIn a 50/30 orientation, the reads consisted of the 50 RACE adaptor
(30 bp; 50-GGACACUGACAUGGACUGAAGGAGUAGAAA-30)
ligated at the novel 50 ends generated on the HCV genome by Slicer
action resulting into an 80-bp read length.
Operating System and Software Environments
All the bioinformatics analyses for this project were undertaken on a
Bio-Linux 8 workstation within an Ubuntu Linux 14.04 LTS base56
and bioinformatics packages updated to their latest available versions
using the default update advisor. Additional packages, such as Cuta-
dapt v1.11, FASTX-Toolkit v0.0.14, and BEDTools v2.26.0, were
downloaded manually from GitHub and their respective online
repositories. Furthermore, the R libraries “Biostrings,” “tools,”
“ShortRead,” and “stringi” were downloaded and installed from the
Rstudio v0.99.903 online repositories (Comprehensive R Archive
Network [CRAN]) and were utilized for .fasta sequence and character
string manipulation.57
RACE Adaptor Trimming
Denise et al.18 removed RACE adapters semi-manually by construct-
ing a custom R script (v2.10.1) using the Bioconductor “ShortRead”
library.58 We used Cutadapt59 instead, to enable simple and tuneable
data processing. Thus, the following parameters were invoked: -g to
set adaptor location on the 50 end of the reads, -e to set mismatch error
tolerance for adaptor alignment, –no-indels to set insertion and dele-
tion tolerance to 0 during adaptor alignment, –discard-untrimmed to
discards reads lacking the full adaptor sequence, and -m to discards
sequences shorter than a given number of nucleotides before and after
adaptor trimming. After adaptor removal, quality analysis was
performed by FastQC (v0.11.3) to check per-base/sequence quality
scores, sequence length distribution, and adaptor content/contamina-
tion. To reduce computational overheads, we implemented
fastx_collapser from the FASTX-Toolkit, which reduces the dataset
size and identiﬁes all the unique sequence products.
Read Alignment
As per Denise et al.,18 we used the ultra-fast, memory-efﬁcient
Burrows-Wheeler transformation algorithm Bowtie v1.1.160 to align
reads to the Con1B reference sequence. Index ﬁles of the Con1B refer-
ence genome were constructed using the “bowtie-build” command.
The Bowtie command was then invoked with the following speciﬁc
parameters: -p that sets the number of threads that will run in separate
cores/processes in parallel, -S that sets the output in .sam format, -k
that outputs only the given number of valid alignments per read, -v
that sets the number of mismatches that are allowed during
alignment, and –al-gz and –un-gz that output two separate ﬁles con-
taining the aligned and unaligned reads, respectively, in .gz compres-
sion for further analysis and processing. Given the prevalence of
Illumina and Ion Torrent systems worldwide, beyond Bowtie1 and
2, we additionally evaluated the impact of Torrent Mapping Align-
ment Program (TMAP), the aligner preferred for Ion Torrent
systems, and we observed no appreciable differences in novel 50 end
detection, provided all other analytical parameters (e.g., >Q30 trim-
ming) are maintained.50 End Counting
The Denise et al.18 pipeline imported the .sam ﬁles into R and
utilized the “Rsamtools” library command “pileup” to count the 50
end of the reads. Here, the Bowtie .sam output ﬁle was viewed using
SAMtools v0.1.19 invoking the “view” command from the com-
mand line.61 The parameters -bS were then used to transcode ﬁles
into the compressed and indexed .bam binary format, a machine-
readable but smaller sized ﬁle. To count the 50 ends of the
reads, the “genomCoverageBed” command (BEDtools v2.26.0)62
was invoked. Speciﬁc parameters included the following: -ibam
that reads the input ﬁles in .bam format, -d that reports the depth
at each genomic position of the reference, and -5 that processes and
calculates the coverage of the 50 positions only instead of the entire
read interval. The output of this command is a 3-column .txt ﬁle
that contains the name of the reference sequence, the nucleotide
position, and the depth of coverage in every position.
Graph Plotting
To plot the graphs of the read counts, we used the R (v3.3.1) statistical
language and the Rstudio v0.99.902 graphical interface.63 Initially, the
“biostrings” and “tools” libraries were loaded in an Rstudio session.
The reference sequence was then imported and manipulated as a
string to attach it to the .txt table containing the read counts. The per-
centage and log10 transformation of the read counts were then calcu-
lated and attached on the table, which was exported as a comma-sepa-
rated value (CSV) object. User-imported settings were then used to
point to the region of interest and the desired nucleotide positions
to be plotted. Finally, a PDF ﬁle was created where percentage and
log10 bar plots were generated and attached. The bar plots were gener-
ated with the R base bar plot command from the corresponding linear
and log10 values. Legends, names, and axis values were then imported
using the text command. An example of the resulting graph is
reported in Figure S5. The resulting “RACE-SEQ lite” pipeline is an
open-source data handling tool available in the GitHub repository
(https://github.com/pantastheo/RACE-SEQ-lite).
Investigating Mismatch Tolerance
To examine how RNAi cleavage is affected by mismatches on the
target sequence, we manipulated mismatch tolerance parameters
during read alignment with Bowtie. Both Bowtie1 and Bowtie2
were evaluated within this analytical process. Using Bowtie1, we
explored the effect of increasing the number of random mismatches
between the RACE-SEQ reads and the reference genome. This was
achieved by carrying out alignments iteratively, each time modifying
the -vmismatch parameter from 0 to 1, 2, or 3 and plotting the result-
ing data. Confusingly for RNAi users, however, Bowtie 2 uses the term
“seed” to deﬁne and extract substrings of deep sequencing reads dur-
ing so-called “multiseed heuristic” alignment.64 Although the net
result is comparable to Bowtie1, Bowtie1 tries to align the entire
read in an end-to-end fashion, which is inherently a slower process
than substring processing.60 However, substring processing impacts
on 50 end deﬁnition for RACE-SEQ by nature of eliminating the
key 50 bases from substrings. Thus, we set the following: -n to set
the number of mismatches permitted in a substring of the sequenceMolecular Therapy: Nucleic Acids Vol. 9 December 2017 31
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Setting the error tolerance explicitly for the seed length speciﬁed and
the length of the substring to be used, we automated the whole process
for one and zero mismatches and three different seed lengths as
follows: “-n0 -l3,” “-n0 -l5,” “-n0 -l10,” “-n1 -l3,” “-n1 -l5,” and “-n1
-l10.” We then ran the dataset through our pipeline and looked for
novel 50 ends ﬂanking the expected cut site (Figure S6).
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